Cargando…
Invasive Breast Carcinoma with Neuroendocrine Differentiation: A Single-Center Analysis of Clinical Features and Prognosis
Introduction Invasive breast cancer with neuroendocrine differentiation is a rare subtype of breast malignancy. Due to frequent changes in the definition of these lesions, the correct diagnosis, estimation of exact prevalence, and clinical behaviour of this entity may be challenging. The aim of this...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747900/ https://www.ncbi.nlm.nih.gov/pubmed/35027862 http://dx.doi.org/10.1055/a-1557-1280 |
_version_ | 1784630940584116224 |
---|---|
author | Krawczyk, Natalia Röwer, Rowena Anlauf, Martin Muntanjohl, Caja Baldus, Stephan Ernst Neumann, Monika Banys-Paluchowski, Maggie Otten, Sabine Luczak, Katharina Ruckhäberle, Eugen Mohrmann, Svjetlana Hoffmann, Jürgen Kaleta, Thomas Jaeger, Bernadette Esposito, Irene Fehm, Tanja |
author_facet | Krawczyk, Natalia Röwer, Rowena Anlauf, Martin Muntanjohl, Caja Baldus, Stephan Ernst Neumann, Monika Banys-Paluchowski, Maggie Otten, Sabine Luczak, Katharina Ruckhäberle, Eugen Mohrmann, Svjetlana Hoffmann, Jürgen Kaleta, Thomas Jaeger, Bernadette Esposito, Irene Fehm, Tanja |
author_sort | Krawczyk, Natalia |
collection | PubMed |
description | Introduction Invasive breast cancer with neuroendocrine differentiation is a rare subtype of breast malignancy. Due to frequent changes in the definition of these lesions, the correct diagnosis, estimation of exact prevalence, and clinical behaviour of this entity may be challenging. The aim of this study was to evaluate the prevalence, clinical features, and outcomes in a large cohort of patients with breast cancer with neuroendocrine differentiation. Patients Twenty-seven cases of breast cancer with neuroendocrine differentiation have been included in this analysis. Twenty-one cases were identified by systematic immunohistochemical re-evaluation of 465 breast cancer specimens using the neuroendocrine markers chromogranin A and synaptophysin, resulting in a prevalence of 4.5%. A further six cases were identified by a review of clinical records. Results Median age at the time of diagnosis was 61 years. 70% of patients had T2 – 4 tumors and 37% were node-positive. The most common immunohistochemical subtype was HR-positive/HER2-negative (85%). 93% were positive for synaptophysin and 48% for chromogranin A. Somatostatin receptor type 2A status was positive in 12 of 24 analyzed tumors (50%). Neuroendocrine-specific treatment with somatostatin analogues was administered in two patients. The 5-year survival rate was 70%. Conclusions Breast cancer with neuroendocrine differentiation is mostly HR-positive/HER2-negative and the diagnosis is made at a higher TNM stage than in patients with conventional invasive breast carcinoma. Moreover, breast cancer with neuroendocrine differentiation was found to be associated with impaired prognosis in several retrospective trials. Due to somatostatin receptor 2A expression, somatostatin receptor-based imaging can be used and somatostatin receptor-targeted therapy can be offered in selected cases. |
format | Online Article Text |
id | pubmed-8747900 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Georg Thieme Verlag KG |
record_format | MEDLINE/PubMed |
spelling | pubmed-87479002022-01-12 Invasive Breast Carcinoma with Neuroendocrine Differentiation: A Single-Center Analysis of Clinical Features and Prognosis Krawczyk, Natalia Röwer, Rowena Anlauf, Martin Muntanjohl, Caja Baldus, Stephan Ernst Neumann, Monika Banys-Paluchowski, Maggie Otten, Sabine Luczak, Katharina Ruckhäberle, Eugen Mohrmann, Svjetlana Hoffmann, Jürgen Kaleta, Thomas Jaeger, Bernadette Esposito, Irene Fehm, Tanja Geburtshilfe Frauenheilkd Introduction Invasive breast cancer with neuroendocrine differentiation is a rare subtype of breast malignancy. Due to frequent changes in the definition of these lesions, the correct diagnosis, estimation of exact prevalence, and clinical behaviour of this entity may be challenging. The aim of this study was to evaluate the prevalence, clinical features, and outcomes in a large cohort of patients with breast cancer with neuroendocrine differentiation. Patients Twenty-seven cases of breast cancer with neuroendocrine differentiation have been included in this analysis. Twenty-one cases were identified by systematic immunohistochemical re-evaluation of 465 breast cancer specimens using the neuroendocrine markers chromogranin A and synaptophysin, resulting in a prevalence of 4.5%. A further six cases were identified by a review of clinical records. Results Median age at the time of diagnosis was 61 years. 70% of patients had T2 – 4 tumors and 37% were node-positive. The most common immunohistochemical subtype was HR-positive/HER2-negative (85%). 93% were positive for synaptophysin and 48% for chromogranin A. Somatostatin receptor type 2A status was positive in 12 of 24 analyzed tumors (50%). Neuroendocrine-specific treatment with somatostatin analogues was administered in two patients. The 5-year survival rate was 70%. Conclusions Breast cancer with neuroendocrine differentiation is mostly HR-positive/HER2-negative and the diagnosis is made at a higher TNM stage than in patients with conventional invasive breast carcinoma. Moreover, breast cancer with neuroendocrine differentiation was found to be associated with impaired prognosis in several retrospective trials. Due to somatostatin receptor 2A expression, somatostatin receptor-based imaging can be used and somatostatin receptor-targeted therapy can be offered in selected cases. Georg Thieme Verlag KG 2021-11-18 /pmc/articles/PMC8747900/ /pubmed/35027862 http://dx.doi.org/10.1055/a-1557-1280 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited. |
spellingShingle | Krawczyk, Natalia Röwer, Rowena Anlauf, Martin Muntanjohl, Caja Baldus, Stephan Ernst Neumann, Monika Banys-Paluchowski, Maggie Otten, Sabine Luczak, Katharina Ruckhäberle, Eugen Mohrmann, Svjetlana Hoffmann, Jürgen Kaleta, Thomas Jaeger, Bernadette Esposito, Irene Fehm, Tanja Invasive Breast Carcinoma with Neuroendocrine Differentiation: A Single-Center Analysis of Clinical Features and Prognosis |
title | Invasive Breast Carcinoma with Neuroendocrine Differentiation: A Single-Center Analysis of Clinical Features and Prognosis |
title_full | Invasive Breast Carcinoma with Neuroendocrine Differentiation: A Single-Center Analysis of Clinical Features and Prognosis |
title_fullStr | Invasive Breast Carcinoma with Neuroendocrine Differentiation: A Single-Center Analysis of Clinical Features and Prognosis |
title_full_unstemmed | Invasive Breast Carcinoma with Neuroendocrine Differentiation: A Single-Center Analysis of Clinical Features and Prognosis |
title_short | Invasive Breast Carcinoma with Neuroendocrine Differentiation: A Single-Center Analysis of Clinical Features and Prognosis |
title_sort | invasive breast carcinoma with neuroendocrine differentiation: a single-center analysis of clinical features and prognosis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747900/ https://www.ncbi.nlm.nih.gov/pubmed/35027862 http://dx.doi.org/10.1055/a-1557-1280 |
work_keys_str_mv | AT krawczyknatalia invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis AT rowerrowena invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis AT anlaufmartin invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis AT muntanjohlcaja invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis AT baldusstephanernst invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis AT neumannmonika invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis AT banyspaluchowskimaggie invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis AT ottensabine invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis AT luczakkatharina invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis AT ruckhaberleeugen invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis AT mohrmannsvjetlana invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis AT hoffmannjurgen invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis AT kaletathomas invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis AT jaegerbernadette invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis AT espositoirene invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis AT fehmtanja invasivebreastcarcinomawithneuroendocrinedifferentiationasinglecenteranalysisofclinicalfeaturesandprognosis |